UBS, Novo Nordisk and CagriSema

Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off "overdone"
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and is in pole position to benefit from strong near-term demand for new weight-loss drugs, according to analysts at UBS.
Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone
UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed”
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from “Neutral” to “Buy.” Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes (T2D) and Wegovy injection for weight management.
Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'
Key Takeaways Novo Nordisk shares rose Wednesday on the company's home market in Denmark and in the U.S. after UBS analysts upgraded the stock.The analysts upgraded the Ozempic obesity drugmaker to a "buy,
UBS Upgrades Novo Nordisk A (NVO)
Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst Price Forecast Suggests 61.15% Upside As of December 23, 2024, the average one-year price target for Novo Nordisk A is $137.
Endocrinology Advisor7d
REDEFINE 1 Trial: Superior Weight Loss Seen With CagriSema
Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes ...
Novo Nordisk Needs Answers to These 5 Key Questions
Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...
The Motley Fool on MSN7d
Should You Buy the Dip in Novo Nordisk Stock Right Now?
Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...
GlobalData on MSN20d
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of ...
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.
FiercePharma1d
Launches from Novo, Lilly top Clarivate's annual 'Drugs to Watch' list
If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...
labiotech1d
Ten drugs to watch in 2025: will these therapies become blockbusters?
A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...